AbbVie Inc (BUE:ABBV)
ARS 21100 275 (1.32%) Market Cap: 326.28 Til Enterprise Value: 391.76 Til PE Ratio: 63.33 PB Ratio: 53.42 GF Score: 74/100

Abbvie Inc at Wolfe Research Healthcare Conference (Virtual) Transcript

Nov 17, 2021 / 02:30PM GMT
Timothy Minton Anderson
Wolfe Research, LLC - MD of Equity Research

Hey, guys. I'm Timothy Anderson. I'm the large-cap pharma and biotech analyst at Wolfe Research. And we're at the start of our healthcare conference that runs today and tomorrow. We'll be talking with AbbVie next here for about the next 40 minutes or so, 3 members of the management team: Mike Severino, who's Vice Chairman and President, heads up R&D, among other things. He has been with the company since 2014. We have Rob Michael, who's EVP and CFO, he's been with the company since 2013; and Jeff Stewart, EVP of Commercial Operations, he's been with the company I think, since 1992, if I got that right; and Liz Shea is somewhere around there as well.

Questions & Answers

Timothy Minton Anderson
Wolfe Research, LLC - MD of Equity Research

So I thought we'd start with some general questions here, and we'll have a wide-ranging discussion, but we'll see what we can get through. But first question, so 2021 coming to an end, 6 weeks left. How is the setup for 2022 looking for AbbVie? I

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot